Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Drug-coated stents effective in ’real world’ patients

23.12.2003


Drug-coated stents are safe and effective at preventing death, heart attack or repeat procedures in "real world" patients who are often sicker or older than those selected for clinical trials, according to a study in today’s rapid issue of Circulation: Journal of the American Heart Association.



The drug-coated stents were more effective than uncoated stents, just as they had been in clinical trials, said lead investigator Patrick W. Serruys, M.D., Ph.D., professor of cardiology at Erasmus Medical Center in Rotterdam, the Netherlands.

This "real world" research is important because patients in clinical trials of drug-coated stents "were a very select group, whereas this registry is an attempt to look at in an unselected population," Serruys said. "Sixty-eight percent of the patients in this study did not meet the selection criteria for the clinical trials."


Stents are tiny flexible wire mesh tubes that prop open blocked arteries in the heart. Drug-eluting stents are coated with slow-release drugs that help prevent cell re-growth that can re-narrow the artery.

These one-year results from the Rampamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry show that 9.7 percent of patients who received the drug-eluting stents had a major adverse cardiac event, compared with 14.8 percent of those treated with bare metal stents.

Only 3.7 percent of the patients treated with drug-eluting stents had a renarrowing of the treated vessel that required repeat procedures, while 10.9 percent of the patients in the bare-metal stent group required repeat interventions.

"The treatment effects – particularly the reduction of reinterventions – were similar across very different subgroups of patients," Serruys said. "The effect was the same in long lesions and short lesions, in small vessels, and in all kinds of anatomic settings."

The study included 508 patients with previously untreated blocked arteries who were treated with sirolimus-eluting Cypher stents. Four hundred fifty patients with similar blockages were treated with bare metal stents. About half of the patients admitted to both groups had acute coronary syndromes (heart attack or angina) and 16 percent in each group also had diabetes. Generally, patients selected for treatment with the coated stents were more likely to have multi-vessel disease, more complicated disease and required more stents than patients treated with uncoated stents.

"We have had basically two major steps in interventional cardiology," Serruys said. "The first was revascularization through percutaneous intervention with the angioplasty balloon in 1977 followed in 1986 by the introduction of the stent. The drug-eluting stent is the next major step."

In an accompanying editorial David P. Faxon, M.D., professor of medicine at the University of Chicago, wrote that the RESEARCH results "go a long way in reassuring the practitioner that drug-eluting stents are in fact safe and effective in a wide variety of patients undergoing ’real world’ angioplasty." The next step should be a mandatory registry established by the Food and Drug Administration to report problems, he said.

Faxon also addressed recent FDA public notifications that warned physicians of sub-acute thrombosis (blood clot) and hypersensitivity reactions linked to using the Cordis Cypher Coronary Stent. "Thus far, 290 cases of sub-acute stent thrombosis have been reported and more than 60 patients have died. But the thrombosis rate is about 1 percent, which is similar to the expected rate for bare metal stents."

###
Serruys’ co-authors are Pedro A. Lemos, M.D.; Ron T. van Domburg, Ph.D.; Francesco Saia, M.D.; Chourmouzios A. Arampatzis, M.D.; Angela Hoye, MB, ChB, MRCP; Muzaffer Degertekin, M.D.; Kengo Tanabe, M.D.; Joost Daemen; Tommy K.K. Liu, Eugene McFadden, M.B., ChB; Georgios Sianos, M.D., Ph.D.; Sjoerd H. Hofma, M.D.; Pieter C. Smits, M.D., Ph.D.; Willem J. van der Giessen, M.D., Ph.D.; and Pim de Feyter, M.D., Ph.D.

CONTACT: For journal copies only,
please call: 214-706-1396


For other information, call:
Carole Bullock: 214-706-1279
Bridgette McNeill: 214-706-1135
Julie Del Barto (broadcast): 214-706-1330

Carole Bullock | EurekAlert!
Further information:
http://www.americanheart.org/

More articles from Studies and Analyses:

nachricht Rutgers-led innovation could spur faster, cheaper, nano-based manufacturing
14.02.2018 | Rutgers University

nachricht New study from the University of Halle: How climate change alters plant growth
12.01.2018 | Martin-Luther-Universität Halle-Wittenberg

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

Im Focus: Interference as a new method for cooling quantum devices

Theoretical physicists propose to use negative interference to control heat flow in quantum devices. Study published in Physical Review Letters

Quantum computer parts are sensitive and need to be cooled to very low temperatures. Their tiny size makes them particularly susceptible to a temperature...

Im Focus: Autonomous 3D scanner supports individual manufacturing processes

Let’s say the armrest is broken in your vintage car. As things stand, you would need a lot of luck and persistence to find the right spare part. But in the world of Industrie 4.0 and production with batch sizes of one, you can simply scan the armrest and print it out. This is made possible by the first ever 3D scanner capable of working autonomously and in real time. The autonomous scanning system will be on display at the Hannover Messe Preview on February 6 and at the Hannover Messe proper from April 23 to 27, 2018 (Hall 6, Booth A30).

Part of the charm of vintage cars is that they stopped making them long ago, so it is special when you do see one out on the roads. If something breaks or...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Fingerprints of quantum entanglement

16.02.2018 | Information Technology

'Living bandages': NUST MISIS scientists develop biocompatible anti-burn nanofibers

16.02.2018 | Health and Medicine

Hubble sees Neptune's mysterious shrinking storm

16.02.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>